Physician profile
Ashley Smith
NPI 1114518065
$1,598.63
in general payments reported to CMS, 2019-2025
14 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $303 · 2023: $550 · 2024: $340 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $573.77 | 2022-2025 | Invega |
| Teva Pharmaceuticals USA, INC. | $291.64 | 2022-2023 | Uzedy, Austedo |
| Lilly USA, LLC | $155.80 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.03 | 2025 | Caplyta |
| Abbvie INC. | $121.98 | 2023 | |
| Neurocrine Biosciences, INC. | $105.23 | 2025 | |
| Novo Nordisk INC | $67.58 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.60 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $30.56 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $22.53 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.20 | 2022 | |
| Conmed Corporation | $18.82 | 2025 | Airseal |
| Novartis Pharmaceuticals Corporation | $14.69 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.20 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.